Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036270 · ClinicalTrials.gov registry record · Phase 3
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 9,779
- Enrollment target
NCT00036270 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 9,779 participants.
The verdict
NCT00036270, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 9,779 participants
- Enrollment target
Study Summary
To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast cancer. This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data will be conducted.
Interventions
- DRUG exemestane (Aromasin)
- DRUG tamoxifen + exemestane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,779 participants |
| Start Date | 2001-08 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036270
The ClinicalTrials.gov registry entry for NCT00036270 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 9,779 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which exemestane (Aromasin) is the first listed.
NCT00036270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036270 about?
NCT00036270 is a clinical study titled "Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane". To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast cancer. This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar ye...
What is the current status of trial NCT00036270?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 9,779 participants. The study started on 2001-08. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00036270?
The interventions under investigation include: exemestane (Aromasin) (DRUG), tamoxifen + exemestane (DRUG).
Who is sponsoring clinical trial NCT00036270?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.